123 related articles for article (PubMed ID: 1637254)
1. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
Neylan TC; van Kammen DP; Kelley ME; Peters JL
Arch Gen Psychiatry; 1992 Aug; 49(8):643-9. PubMed ID: 1637254
[TBL] [Abstract][Full Text] [Related]
2. Electroencephalographic sleep in clinically stable schizophrenic patients: two-weeks versus six-weeks neuroleptic-free.
Nofzinger EA; van Kammen DP; Gilbertson MW; Gurklis JA; Peters JL
Biol Psychiatry; 1993 Jun 1-15; 33(11-12):829-35. PubMed ID: 8104041
[TBL] [Abstract][Full Text] [Related]
3. Effects of antipsychotic treatment on polysomnographic measures in schizophrenia: a replication and extension.
Maixner S; Tandon R; Eiser A; Taylor S; DeQuardo JR; Shipley J
Am J Psychiatry; 1998 Nov; 155(11):1600-2. PubMed ID: 9812125
[TBL] [Abstract][Full Text] [Related]
4. Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism.
Thaker GK; Wagman AM; Kirkpatrick B; Tamminga CA
Biol Psychiatry; 1989 Jan; 25(1):75-86. PubMed ID: 2563233
[TBL] [Abstract][Full Text] [Related]
5. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs.
Wetter TC; Lauer CJ; Gillich G; Pollmächer T
J Psychiatr Res; 1996; 30(6):411-9. PubMed ID: 9023785
[TBL] [Abstract][Full Text] [Related]
6. Sleep polygraphy in schizophrenia: methodological issues.
Thaker GK; Wagman AM; Tamminga CA
Biol Psychiatry; 1990 Aug; 28(3):240-6. PubMed ID: 1974153
[TBL] [Abstract][Full Text] [Related]
7. Noradrenergic activity and prediction of psychotic relapse following haloperidol withdrawal in schizophrenia.
van Kammen DP; Agren H; Yao JK; O'Connor DT; Gurklis J; Peters JL
Am J Psychiatry; 1994 Mar; 151(3):379-84. PubMed ID: 7509126
[TBL] [Abstract][Full Text] [Related]
8. CSF levels of diazepam-binding inhibitor correlate with REM latency in schizophrenia, a pilot study.
van Kammen DP; Guidotti A; Neylan T; Guarneri P; Kelley ME; Gurklis J; Gilbertson MW; Peters JL; Costa E
Eur Arch Psychiatry Clin Neurosci; 1994; 244(4):216-22. PubMed ID: 7888420
[TBL] [Abstract][Full Text] [Related]
9. Effect of neuroleptic treatment on polysomnographic measures in schizophrenia.
Taylor SF; Tandon R; Shipley JE; Eiser AS
Biol Psychiatry; 1991 Nov; 30(9):904-12. PubMed ID: 1684117
[TBL] [Abstract][Full Text] [Related]
10. Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients.
Steinhauer SR; van Kammen DP; Colbert K; Peters JL; Zubin J
Psychiatry Res; 1992 Sep; 43(3):287-98. PubMed ID: 1438625
[TBL] [Abstract][Full Text] [Related]
11. Sleep architecture and its clinical correlates in first episode and neuroleptic-naive patients with schizophrenia.
Poulin J; Daoust AM; Forest G; Stip E; Godbout R
Schizophr Res; 2003 Jul; 62(1-2):147-53. PubMed ID: 12765755
[TBL] [Abstract][Full Text] [Related]
12. Sleep and the cholinergic rapid eye movement sleep induction test in patients with primary alcohol dependence.
Gann H; Feige B; Hohagen F; van Calker D; Geiss D; Dieter R
Biol Psychiatry; 2001 Sep; 50(5):383-90. PubMed ID: 11543743
[TBL] [Abstract][Full Text] [Related]
13. CSF noradrenergic activity and sleep EEG in clinically stable schizophrenic patients after haloperidol withdrawal.
van Kammen DP; Yao J; Gurklis J; O'Connor D; Nofzinger E; Peters JL
Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():325A-326A. PubMed ID: 1498856
[No Abstract] [Full Text] [Related]
14. A longitudinal study of EEG sleep in schizophrenia.
Keshavan MS; Reynolds CF; Miewald JM; Montrose DM
Psychiatry Res; 1996 Jan; 59(3):203-11. PubMed ID: 8930026
[TBL] [Abstract][Full Text] [Related]
15. Digital computer analyzed sleep and resting EEG during haloperidol treatment.
Itil TM; Gannon P; Hsu W; Klingenberg H
Am J Psychiatry; 1970 Oct; 127(4):462-71. PubMed ID: 4318894
[No Abstract] [Full Text] [Related]
16. Electroencephalographic sleep abnormalities in schizophrenia. Relationship to positive/negative symptoms and prior neuroleptic treatment.
Tandon R; Shipley JE; Taylor S; Greden JF; Eiser A; DeQuardo J; Goodson J
Arch Gen Psychiatry; 1992 Mar; 49(3):185-94. PubMed ID: 1348923
[TBL] [Abstract][Full Text] [Related]
17. Delta sleep-inducing-peptide-like immunoreactivity (DSIP-LI) and delta sleep in schizophrenic volunteers.
van Kammen DP; Widerlöv E; Neylan TC; Ekman R; Kelley ME; Mouton A; Peters JL
Sleep; 1992 Dec; 15(6):519-25. PubMed ID: 1475566
[TBL] [Abstract][Full Text] [Related]
18. Effects of fluvoxamine and paroxetine on sleep structure in normal subjects: a home-based Nightcap evaluation during drug administration and withdrawal.
Silvestri R; Pace-Schott EF; Gersh T; Stickgold R; Salzman C; Hobson JA
J Clin Psychiatry; 2001 Aug; 62(8):642-52. PubMed ID: 11561938
[TBL] [Abstract][Full Text] [Related]
19. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design.
Dixon L; Thaker G; Conley R; Ross D; Cascella N; Tamminga C
Schizophr Res; 1993 Oct; 10(3):267-71. PubMed ID: 8260445
[TBL] [Abstract][Full Text] [Related]
20. CSF chromogranin A-like immunoreactivity in schizophrenia: relationships with REM latency and slow wave sleep.
van Kammen DP; O'Connor DT; Neylan TC; Mouton A; Gurklis JA; Gilbertson MW; Peters JL
Psychiatry Res; 1992 Apr; 42(1):53-63. PubMed ID: 1603881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
